Yang Xiaojing, Feng Min, Jiang Xia, Wu Zhenlong, Li Zhimei, Aau Meiyee, Yu Qiang
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672.
Genes Dev. 2009 Oct 15;23(20):2388-93. doi: 10.1101/gad.1819009.
The Rb-E2F pathway drives cell cycle progression and cell proliferation, and the molecular strategies safeguarding its activity are not fully understood. Here we report that E2F1 directly transactivates miR-449a/b. miR-449a/b targets and inhibits oncogenic CDK6 and CDC25A, resulting in pRb dephosphorylation and cell cycle arrest at G1 phase, revealing a negative feedback regulation of the pRb-E2F1 pathway. Moreover, miR-449a/b expression in cancer cells is epigenetically repressed through histone H3 Lys27 trimethylation, and epigenetic drug treatment targeting histone methylation results in strong induction of miR-449a/b. Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer.
Rb-E2F通路驱动细胞周期进程和细胞增殖,而保障其活性的分子策略尚未完全明确。在此,我们报道E2F1直接反式激活miR-449a/b。miR-449a/b靶向并抑制致癌性CDK6和CDC25A,导致pRb去磷酸化并使细胞周期停滞在G1期,揭示了pRb-E2F1通路的负反馈调节。此外,癌细胞中miR-449a/b的表达通过组蛋白H3赖氨酸27三甲基化被表观遗传抑制,而针对组蛋白甲基化的表观遗传药物治疗可强烈诱导miR-449a/b。我们的研究揭示了miR-449a/b通过调节Rb/E2F1活性发挥肿瘤抑制功能,并表明通过异常表观遗传事件逃避这种调节有助于人类癌症中E2F1失调和不受限制的增殖。